Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trident
NCT02013674Phase 2Completed
- Start
- Feb 2014
- Primary completion
- Mar 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived human mesenchymal stem cells in ischemic cardiomyopathy (ICM). Started Feb 2014; status: completed.
02
Drugs
allogeneic bone marrow-derived human mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02013674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013674.